Table 4 Adverse events experienced by the duloxetine treatment group
Duloxetine intervention N = 57 – n (%)* | |
|---|---|
Experienced an AE | 54 (94.7%) |
Discontinued due to AE(s) | 12 (21.1%) |
Number of AEs per patient, median (Q1;Q3) | 3 (2;5) |
AEs in ≥5% of patients | |
Headache | 19 (33.3%) |
Somnolence | 17 (29.8%) |
Nausea | 16 (28.1%) |
Dry mouth | 16 (28.1%) |
Constipation | 12 (21.1%) |
Fatigue | 10 (17.5%) |
Dizziness | 10 (17.5%) |
Insomnia | 7 (12.3%) |
Hyperhidrosis | 6 (10.5%) |
Paresthesia | 6 (10.5%) |
Diarrhea | 4 (7.0%) |
Dyspepsia | 4 (7.0%) |
Dysuria | 4 (7.0%) |
Hot flushes | 4 (7.0%) |
Vomiting | 4 (7.0%) |
Palpations | 3 (5.3%) |
Blurred vision | 3 (5.3%) |
Musculoskeletal pain | 3 (5.3%) |